Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(lg)] gene modified T lymphocytes

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 2, 2004, Pages 134-140

  Lamers, C H J ^a   Sleijfer, S ^a   Willemsen, R A ^a   Debets, R ^a   Kruit, W H J ^a   Gratama, J W ^a   Stoter, G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical study; Human T lymphocytes; Immunogene therapy; Renal cell carcinoma; Single chain chimeric receptor

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; AUTOTRANSPLANTATION; CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOCOMPETENCE; IN VITRO STUDY; INDIVIDUALIZATION; KIDNEY CANCER; LIVER DISEASE; LYMPHOCYTE TRANSFER; MOUSE; NEPHRECTOMY; NONHUMAN; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 5744254376     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Muehlbauer PM, Schwartzentruber DJ. Cancer vaccines. Semin Oncol Nurs 2003; 19: 206-16.
2. Acres B, Paul S, Haegel-Kronenberger H, Calmels B, Squiban P. Therapeutic cancer vaccines. Curr Opin Mol Ther 2004; 6: 40-7.
3. Dudley ME, Wunderlich IR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 5594: 850-4.
4. Yee C, Thompson JA, Byrd D, et al. Adoptive T-cell therapy using antigen-specific CD8+ T-cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T-cells. Proc Natl Acad Sci USA 2002; 25: 16168-73.
5. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
6. Bolhuis RLH, Lamers CHJ, Goey SH, et al. Adoptive immunotherapy of ovarian carcino-ma with Bs-Mab-targeted lymphocytes: a multi-center study. Int J Cancer 1992; 7: 78-81.
7. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intra-peritoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 19: 1463-9.
8. Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, et al. Clustered CD3/TCR complexes do not transduce activation signals following bispecific monoclonal antibody triggered lysis by CTL via CD3. J Immunol 1993; 151: 2904-14.
9. Lamers CHJ, Gratama JW, Warnaar SO, et al. Inhibition of bispecific monoclonal antibody (bs-Ab)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated lymphocytes. Int J Cancer 1995; 60: 450-7.
10. Willemsen RA, Debets R, Chames P, Bolhuis RLH. Genetic engeneering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003; 64: 56-68.
11. Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH. Single chain immunoglobulin/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells and recycle lytic capacity. J Immunol 1996; 157: 836-43.
12. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507-13.
13. Willemsen RA, Weijtens MEM, Ronteltap C, et al. Genetic programming of primary human T lymphocytes with cancer specific chimeric single chain and two chain TCR. Gene Ther 2000; 7: 1369-77.
14. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RLH, Chames P. A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for targeting of primary human T lymphocytes. Gene Ther 2001; 8: 1601-8.
15. Debets R, Willemsen RA, Bolhuis RLH. Adoptive transfer of T-cell immunity: Gene transfer with MHC-restricted receptors. Trends Immunol 2002; 23: 435-6.
16. Chames P, Willemsen RA, Rojas G, et al. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol 2002; 169: 1110-8.
17. Weijtens ME, Willemsen RA, Hart E, Bolhuis RLH. A retroviral vector system "Stitch"in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient transduction and expression in human T lymphocytes. Gene Ther 1998; 5: 1195-203.
18. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 1999; 6: 412-9.
19. Geiger TL, Leitenberg D, Flavell RA. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. J Immunol 1999; 162: 5931-9.
20. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996; 26: 2304-9.
21. Hombach A, Sent D, Schneider C, et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61: 1976-82.
22. Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169: 5780-6. Erratum in: J Immunol 2003; 170: 3440.
23. Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155-63. Erratum in: Blood 2003; 101: 3808.
24. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: Teaching old 'magic bullets'new tricks. Trends Immunol 2004; 5: 85-91.
25. Darcy PK, Haynes NM, Snook MB, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000; 164: 3705-12.
26. Weijtens ME, Hart EH, Bolhuis RLH. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 2000; 7: 35-42.
27. Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RLH. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 1998; 77: 181-7.
28. Hekele A, Dall P, Moritz D, et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 1996; 68: 232-8.
29. Altenschmidt U, Klundt E, Groner, B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997; 159: 5509-15.
30. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55: 3369-73.
31. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nature Med 1998; 4: 168-72.
32. Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif 2002; 20: 315-41.
33. Pinthus JH, Waks T, Kaufman-Francis K, et al. Immunogene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003; 63: 2470-6.
34. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-74.
35. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
36. Bolhuis RL, Willemsen RA, Lamers CH, Stam K, Gratama JW, Weijtens ME. Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients. Adv Exp Med Biol 1998; 451: 547-55.
37. Lamers CHJ, Willemsen RA, Luider B, Debets R, Bolhuis RLH. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 2002; 9: 613-23.
38. Oosterwijk E, Ruiter DJ, Hoedemaeker PHJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-94.
39. Oosterwijk E, Debruyne FMJ, Schalken, JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Sem Oncol 1995; 2: 34-41.
40. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5 (Suppl.): S3268-74.
41. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 985-90.
42. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-37.
43. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999; 19: 1197-200.
44. Steffens MG, Boerman OC, Oyen WJ, et al. Intra-tumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res 1999; 59: 1615-9.
45. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
46. Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: Implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998; 4: 75-83.
47. Gross G, Levy S, Levy R, Waks T, Eshhar Z. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: A model for tumour immunotherapy. Biochem Soc Trans 1995; 23: 1079-82.
48. Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999; 5: 3928-41.
49. Hombach A, Heuser C, Sircar R, et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997; 113: 1163-70.
50. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993; 151: 6577-82.
51. Reinhold U, Liu L, Ludtke-Handjery HC, et al. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Invest Dermatol 1999; 112: 744-50.
52. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178: 361-6.
53. Roberts MR, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994; 84: 2878-89.
54. Yang OO, Tran AC, Kalams SA, et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 1997; 94: 11478-83.